التفاصيل البيبلوغرافية
| العنوان: |
Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line. |
| المؤلفون: |
Xavier, Alcides Euzebio Tavares, Veronez, Luciana Chain, Nagano, Luís Fernando Peinado, Correa, Carolina Alves Pereira, Baroni, Mirela, Ramos, Milena Silva, Queiroz, Rosane de Gomes de Paula, Fernandes Molina, Carlos Augusto, Yunes, José Andres, Brandalise, Silvia Regina, Antonini, Sonir Antonio Rauber, Tone, Luiz Gonzaga, Valera, Elvis Terci, Scrideli, Carlos Alberto |
| المصدر: |
Cancers; Mar2024, Vol. 16 Issue 6, p1094, 20p |
| مصطلحات موضوعية: |
PROTEINS, IN vitro studies, NF-kappa B, RESEARCH funding, CANCER relapse, SURVIVAL rate, CELL proliferation, TREATMENT effectiveness, TUMOR markers, AMP-activated protein kinases, MULTIVARIATE analysis, AGE distribution, CANCER patients, CELLULAR signal transduction, CYTOSKELETAL proteins, CELL motility, GENE expression, CELL lines, METASTASIS, MTOR inhibitors, ADRENAL tumors, POLYPHENOLS, WNT proteins, TUMOR necrosis factors, PHARMACODYNAMICS |
| مصطلحات جغرافية: |
BRAZIL |
| مستخلص: |
Simple Summary: Adrenocortical tumors are rare neoplasms with an uncertain prognosis. A greater understanding of the biology of these tumors will allow new therapeutic targets to be identified and the prognosis of these patients to be better understood, enabling more precise therapeutic targeting. Our study sought to evaluate the expression of the PRKAB2 gene as a prognostic biomarker in 63 cases of pediatric adrenocortical tumors and to analyze how efficient Rottlerin is in altering the tumorigenic profile of the NCI-H295R adrenocortical carcinoma (ACC) cell line. Pediatric adrenocortical tumors (ACTs) are rare, highly heterogeneous neoplasms with limited therapeutic options, making the investigation of new targets with potential therapeutic or prognostic purposes urgent. The PRKAB2 gene produces one of the subunits of the AMP-activated protein kinase (AMPK) complex and has been associated with cancer. However, little is known about the role AMPK plays in ACTs. We have evaluated how PRKAB2 is associated with clinical and biological characteristics in 63 pediatric patients with ACTs and conducted in vitro studies on the human NCI-H295R ACC cell line. An analysis of our cohort and the public ACC pediatric dataset GSE76019 showed that lower PRKAB2 expression was associated with relapse, death, metastasis, and lower event-free and overall survival rates. Multivariate analysis showed that PRKAB2 expression was an independent prognostic factor when associated with age, tumor weight and volume, and metastasis. In vitro tests on NCI-H295R cells demonstrated that Rottlerin, a drug that can activate AMPK, modulated several pathways in NCI-H295R cells, including AMPK/mTOR, Wnt/β-catenin, SKP2, HH, MAPK, NFKB, and TNF. Treatment with Rottlerin decreased cell proliferation and migration, clonogenic capacity, and steroid production. Together, these results suggest that PRKAB2 is a potential prognostic marker in pediatric ACTs, and that Rottlerin is promising for investigating drugs that can act against ACTs. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder